IO Biotech, Inc. (IOBT) shares fell 34.25 percent to $1.19, down $0.62 on Monday, after the company announced topline results from its pivotal Phase 3 trial of the cancer vaccine Cylembio in combination with Merck's KEYTRUDA for advanced melanoma. While the treatment showed an improvement in progression-free survival over KEYTRUDA alone, it narrowly missed statistical significance for the primary endpoint.
The stock opened at $1.88 and traded between $1.18 and $2.04, with volume surging to 70.37 million shares, far above the average of 0.32 million on the Nasdaq.
IO Biotech's 52-week range is $0.66 to $2.48.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.